Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fat Tissue's chemical signals: a new target for diabetes?

NCT ID NCT04940962

NEW Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers collect small samples of abdominal fat during planned surgery to study how fat tissue releases chemical messengers called endocannabinoids. They compare samples from people with obesity, with or without type 2 diabetes, to samples from people without these conditions. The goal is to understand whether fat tissue overproduces these messengers and whether blocking a receptor called CB1 can reduce that production. The study does not test a treatment in patients; it examines tissue in the laboratory.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers learn how fat tissue releases these signals, it could point toward new ways to treat obesity and type 2 diabetes.
What could go wrong
This is a small laboratory study of tissue samples, not a treatment trial. It may not lead to any new therapy, and the findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Sep 2021

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Controls: * men or post-menopausal women aged between 18 and 80 * gave oral consent * to undergo visceral surgery Non-diabetic obese subjects: * men or post-menopausal women aged between 18 and 80 * BMI \> 30 * gave oral consent * to undergo visceral surgery Obese diabetic subjects: * men or post-menopausal women aged between 18 and 80 * type 2 diabetic not treated with Insulin or GLP-1 agonist * BMI \> 30 * gave oral consent * to undergo visceral surgery Exclusion Criteria: * Controls: * Person not covered by national health insurance. * BMI \> 30 * diabetes * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * protected adult Non-diabetic obese subjects: * Person not covered by national health insurance * diabetes * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * protected adult Obese diabetic subjects: * Person not covered by national health insurance * chronic inflammatory disease * cancer undergoing chemotherapy or chemotherapy less than a year old * digestive cancer with recent weight loss (≥10%) and/or malnutrition * known metastatic cancer * cancer undergoing long-term hormonal treatment * type 1 diabetes * secondary diabetes * protected adult

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity, Abdominal type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal obesity Diabete type 2

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.